“Move over CAR-T: the potential of NK cells in cell therapy” On this pharmaphorum podcast, Artiva’s CEO, Dr. Fred Aslan, talks with host Jonah Comstock about the potential of NK cells as an allogeneic cell therapy approach in autoimmune disease and the importance of a robust manufacturing process. Listen to the podcast on pharmaphorum’s website, which has a podcast player or the option to download the episode. It also has links to find the podcast on iTunes, Spotify, and Stitcher. https://lnkd.in/gc6vDjRf #AlloNK #NKcell #NKcells #clinicaltrials #clinicaltrial #autoimmunedisease #lupus #autoimmunity #celltherapy
Artiva Biotherapeutics
Biotechnology Research
San Diego, California 8,735 followers
We are dedicated to making safe and effective cell therapies accessible to any cancer patient who may benefit.
About us
Artiva Biotherapeutics is an immunotherapy company with the ability to produce off-the-shelf, allogeneic NK cell therapies at a massive scale. Our mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Our lead program, AlloNK®, is an allogeneic, non-genetically modified NK cell therapy candidate designed to enhance the activity of monoclonal antibodies or NK cell engagers. AlloNK is currently in clinical trials in combination with rituximab for treatment of systemic lupus erythematosus (SLE) in patients with active lupus nephritis and for treatment of Non-Hodgkin Lymphoma, as well as in combination with Affimed’s innate cell engager AFM13 for the treatment of patients with relapsed/refractory CD30-positive lymphomas.
- Website
-
http://www.artivabio.com
External link for Artiva Biotherapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Diego, California
- Type
- Privately Held
- Founded
- 2019
- Specialties
- cell therapy, cancer, nk cells, nk cell therapy, and car-nk
Locations
-
Primary
5505 Morehouse Drive, Suite 100
San Diego, California 92121, US
Employees at Artiva Biotherapeutics
Updates
-
We were thrilled to be with #LupusTherapeutics and @LupusResearchAlliance at the fourth annual Lupus Clinical Investigators Network (LuCIN) Community Meeting, bringing together clinical investigators, study coordinators, people with lupus and industry partners to participate in discussions around critical research initiatives and the latest approaches in lupus treatment. Visit https://bit.ly/LuCIN2024 to learn more about LuCIN. #LupusClinicalResearch #LuCINCommunity #LupusAwarenessMonth
-
Join us in raising awareness for Lupus Day! #WorldLupusDay #MakeLupusVisible #may10worldlupusday 💜🦋
-
We say “manufacturing first,” but what does that mean, and why is it important for NK cell therapy? Our Chief Technical Operations Officer, Chris Horan, answers these questions and more for Cell and Gene. Read the article here: https://lnkd.in/dd4Y9pwT #AlloNK #NKcell #NKcells #clinicaltrials #clinicaltrial #autoimmunedisease #lupus #autoimmunity
NK Cell Therapies: How Artiva Biotherapeutics Leverages Its "Manufacturing First" Approach
cellandgene.com
-
We are excited to announce that we’ve appointed Neha Krishnamohan as Chief Financial Officer (CFO) and EVP, Corporate Development and promoted Jennifer Bush to Chief Operating Officer. Welcome to the team, Neha, and congrats, Jennifer! Read the full release here: https://lnkd.in/gnrwX4K5 #AlloNK #NKcell #NKcells #clinicaltrials #clinicaltrial #autoimmunedisease #lupus #autoimmunity
Artiva Biotherapeutics Readies for the Next Phase of Growth with the Appointment of Neha Krishnamohan as CFO and EVP, Corporate Development and Promotion of Jennifer Bush to Chief Operating Officer - Artiva Biotherapeutics
artivabio.com
-
We are excited to announce that we’ve dosed our first patient in a Phase 1 clinical trial of #AlloNK in lupus nephritis. Our CEO Fred Aslan said in today’s press release, “To our knowledge, this is the first time a patient has received an allogeneic NK cell therapy candidate in a U.S. clinical trial for treatment of an autoimmune disease. We are encouraged by the activity of AlloNK in our NHL trial, demonstrating AlloNK’s ability to drive B-cell depletion and helping validate the therapy’s potential mechanism of action. Furthermore, our ability to combine AlloNK with CD20, CD19, or CD38 directed monoclonal antibodies gives AlloNK the versatility to target distinct B-cell subpopulations across different autoimmune diseases.” Thank you to the Artiva team for all your hard work supporting the initiation of our multicenter clinical trial! Read the full release here: https://lnkd.in/gM_t_TEN #AlloNK #NKcell #NKcells #clinicaltrials #clinicaltrial #autoimmunedisease #lupus #autoimmunity
Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis
artivabio.com
-
“We can do more.” These have been the guiding words from the founding days of Artiva. This is why we are excited to work with Lupus Therapeutics and the @Lupus Research Alliance who will provide clinical operations support to advance AlloNK, an off-the-shelf, allogeneic NK cell therapy, for the treatment of lupus nephritis. Lupus nephritis is a severe autoimmune disease with limited treatment options. Our NK cell therapy has a mechanism very similar to the B-cell targeted autologous CAR-T therapies, but that supports improved access for patients, without the need for apheresis and hospitalization. Read the release here: https://lnkd.in/gqiBGUHx #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis
Lupus Therapeutics Announces Collaboration to Support the Evaluation of Non-Genetically Modified Cell-Based Therapy for Lupus Nephritis with Artiva Biotherapeutics - Lupus Research
lupusresearch.org
-
Next week, our CEO Fred Aslan will be speaking on a key panel to discuss the tremendous opportunity for NK cell therapies and what near-term milestones are coming for the field. If you can’t attend Hanson Wade Group Innate Killers Summit in San Diego next week, this interview with BiotechTV provides great info about our preliminary clinical data in cancer and our upcoming clinical trials in autoimmune disease. To learn more about the conference, visit: https://innate-killer.com/ Watch the BiotechTV interview with Brad Loncar here: https://lnkd.in/gmChSaTD #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis #cancer
Home | Innate Killer Summit
innate-killer.com
-
Happy #InternationalWomensDay! Today, we celebrate the incredible accomplishments of women all over the globe. At Artiva, we are proud to have a team that champions diversity and inclusion. On this special day, we want to give a shoutout to the incredible women who make up 50% of our team - thank you for your incredible contributions and for inspiring us every day! #IWD2024 #InspireInclusion #Artivabio
-
Thanks BiotechTV for chatting with our CEO Fred Aslan about using #NKcell therapies for #autoimmunedisease and #cancer. He describes how Artiva is harnessing the ability of #NKcells to act as a modulator of antibody dependent cellular cytotoxicity as a therapeutic property of its cell therapies. Watch the video below or here: https://lnkd.in/gmChSaTD
𝐒𝐚𝐧 𝐃𝐢𝐞𝐠𝐨: With seemingly every CAR-T company getting into autoimmune disease, San Diego based Artiva Biotherapeutics thinks there is a better way with NK cells. CEO Fred Aslan explains the rationale. Full video: https://lnkd.in/gmChSaTD BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | Allucent | NYSE